Metamizol Al (Metamizole Sodium Monohydrate)

Metamizole sodium works by inhibiting cyclo‑oxygenase enzymes, which reduces the synthesis of prostaglandins that sensitize pain receptors. It also modulates central pain pathways in the spinal cord and influences hypothalamic temperature regulation, providing both analgesic and antipyretic effects.

The dose of Metamizol Al is individualized by the prescribing healthcare professional based on the patient’s condition, severity of symptoms, and clinical response. No fixed dosing regimen is provided here; the prescriber determines the appropriate amount and frequency.

Safety data for Metamizol sodium during pregnancy and lactation are limited. Because of potential risks, it is generally recommended to avoid use unless the benefit clearly outweighs the potential harm, and alternative therapies should be considered when possible.

To order Metamizol Al, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The sales team will then reply with pricing, availability, shipping details and any required import documentation.

Metamizol belongs to the pyrazolone class, which differs from traditional NSAIDs such as ibuprofen or naproxen. While both reduce pain and fever, Metamizol often provides stronger analgesia for severe pain and has a lower risk of gastrointestinal irritation, but it carries a unique risk of blood‑cell disorders that requires monitoring.

Metamizol Al tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in damp or excessively hot environments.

Metamizol Al is taken orally, usually with a full glass of water. The tablet should be swallowed whole and not crushed or chewed unless specifically instructed by a healthcare professional. It is typically taken with or without food, depending on the prescriber's guidance.

The most serious adverse reactions include agranulocytosis, a potentially life‑threatening drop in white blood cells; severe skin reactions such as Stevens‑Johnson syndrome; and anaphylactic shock. Prompt medical attention is required if symptoms such as fever, sore throat, rash, or difficulty breathing develop.

Metamizol Al should be avoided in individuals with known hypersensitivity to Metamizole or other pyrazolones, in patients with a history of severe blood‑cell disorders, and in those with uncontrolled hypotension. Caution is also advised for pregnant women, nursing mothers, and patients with significant liver or kidney impairment.